The website will be undergoing scheduled maintenance from 6.00pm to 11.30pm on 14 March 2023, and will not be available during this period. We apologise for any inconvenience.
Updates on COVID-19 financing schemes
Updates on COVID-19 financing schemes
From 1 April 2023, COVID-19-related financing support will be re-aligned to that of other acute illnesses
min read Published on 09 Feb 2023


As Singapore treats COVID-19 as an endemic disease, financing support for COVID-19 testing and treatment will be scaled back and re-aligned to that of other acute illnesses. From 1 April 2023^, the following changes will be implemented:

Hospitals and COVID-19 Treatment Facilities (CTFs)

  • No 100% subsidy will be provided to all patients*, regardless of vaccination status, who visit a hospital or CTF for COVID-19 treatment.
  • Government subsidies, MediShield Life and MediSave will apply to SCs and PRs.
  • Financial assistance will be available to lower income Singaporeans.

Community Isolation Facilities (CIFs)

  • No longer be required for COVID-19.
  • Some CIFs will be retained for COVID-19 patients who want to self-isolate for valid reasons. However, all occupants* will be charged for their stay.
  • As CIFs are not medical facilities, Government subsidies, MediShield Life or MediSave cannot be tapped on to pay the bill.

Primary care settings (Polyclinics and GP clinics)

  • All patients will be required to pay for any COVID-19 testing, subject to prevailing subsidies.

^ Applies to new admissions in public hospitals, COVID-19 Treatment Facilities and Community Isolation Facilities from 1 April 2023

* Includes Singapore Citizens, Permanent Residents and Long-Term Pass Holders (SCs/PRs/LTPHs

COVID-19 vaccinations and oral antivirals will remain fully subsidised for clinically eligible patients in outpatient (including primary care), ambulatory settings of public hospitals and nursing homes, until further notice. Free telemedicine support will also be available to patients with a higher risk of severe COVID-19, such as the immunocompromised and individuals with some comorbidities.


For more information, please refer to MOH’s press release.